1.88
-0.03(-1.57%)
Currency In USD
| Previous Close | 1.91 |
| Open | 1.94 |
| Day High | 1.96 |
| Day Low | 1.85 |
| 52-Week High | 1.96 |
| 52-Week Low | 0.52 |
| Volume | 6.98M |
| Average Volume | 3.9M |
| Market Cap | 587.16M |
| PE | -8.55 |
| EPS | -0.22 |
| Moving Average 50 Days | 1.35 |
| Moving Average 200 Days | 1.14 |
| Change | -0.03 |
If you invested $1000 in Ocugen, Inc. (OCGN) 10 years ago, it would be worth $12.84 as of January 14, 2026 at a share price of $1.88. Whereas If you bought $1000 worth of Ocugen, Inc. (OCGN) shares 5 years ago, it would be worth $862.39 as of January 14, 2026 at a share price of $1.88.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcas
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
GlobeNewswire Inc.
Jan 12, 2026 11:30 AM GMT
Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN),
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
GlobeNewswire Inc.
Jan 09, 2026 12:02 PM GMT
MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-founde